Natixis’s Corcept Therapeutics CORT Stock Holding History

Natixis’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.27K	Buy	+81	New	+$3.03K	﹤0.01%	1047
2021 Q2	–	Sell	-9,300	Closed	-$221K	–	875
2021 Q1	$221K	Hold	9,300	–	–	﹤0.01%	1018
2020 Q4	$243K	Buy	+9,300	New	+$196K	﹤0.01%	982
2017 Q4	–	Sell	-11,354	Closed	-$219K	–	897
2017 Q3	$219K	Buy	+11,354	New	+$169K	﹤0.01%	1086
2014 Q2	–	Sell	-11,500	Closed	-$50K	–	469
2014 Q1	$50K	Buy	+11,500	New	+$40.2K	﹤0.01%	491

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Natixis's CORT Position: Q1 2026 in Review

Natixis opened a new position in Corcept Therapeutics (CORT) in Q1 2026: 81 shares worth $3.27K. The stake represents ﹤0.01% of the portfolio and ranks #1047 among its holdings. This is a return to the name: Natixis previously reported a position in CORT as recently as Q1 2021.

Natixis first reported a position in CORT in Q1 2014 and has held it in 5 quarters since. The position peaked at $243K in Q4 2020. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

Natixis held 81 shares of Corcept Therapeutics worth $3.27K as of Q1 2026.
Corcept Therapeutics was a new Natixis position in Q1 2026.
Corcept Therapeutics made up ﹤0.01% of Natixis's portfolio in Q1 2026, its #1047 holding.
Natixis first reported a position in Corcept Therapeutics in Q1 2014 and has held it in 5 quarters since.
Natixis's Corcept Therapeutics position peaked at $243K in Q4 2020.
351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.